DDInter775 DDInter899
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fondaparinux {u} (Compound) binds {v} (Gene) F10
Fondaparinux {u} (Compound) is included by {v} (Pharmacologic Class) Factor Xa Inhibitors
Fondaparinux {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Fondaparinux {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Choline salicylate
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rofecoxib
Fondaparinux {u} may lead to a major life threatening interaction when taken with {v} Cilostazol
Fondaparinux {u} may lead to a major life threatening interaction when taken with {v} Streptokinase
Fondaparinux {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Ardeparin
Fondaparinux (Compound) binds F10 (Gene)
Fondaparinux (Compound) is included by Factor Xa Inhibitors (Pharmacologic Class)
Fondaparinux (Compound) causes Hypersensitivity (Side Effect)
Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Capsicum
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Fondaparinux may lead to a major life threatening interaction when taken with Cilostazol
Fondaparinux may lead to a major life threatening interaction when taken with Streptokinase
Fondaparinux (Compound) resembles Ardeparin (Compound) and Fondaparinux may lead to a major life threatening interaction when taken with Ardeparin